Global Dental Partnering 2010 to 2020 provides the full collection of Dental disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
Trends in Dental partnering deals Financial deal terms for headline, upfront and royalty by stage of development Dental partnering agreement structure Dental partnering contract documents Top Dental deals by value Most active Dental dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Dental disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dental deals.
The report presents financial deal terms values for Dental deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Dental dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Dental dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Dental deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Dental dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Dental deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Dental partnering deals by specific Dental target announced since 2010. The chapter is organized by specific Dental therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Dental partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Dental partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Dental technologies and products.
Report scope Global Dental Partnering 2010 to 2020 is intended to provide the reader with an in-depth understanding and access to Dental trends and structure of deals entered into by leading companies worldwide.
Global Dental Partnering 2010 to 2020 includes: Trends in Dental dealmaking in the biopharma industry since 2010 Analysis of Dental deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Dental deal contract documents Comprehensive access to over 250 Dental deal records The leading Dental deals by value since 2010 Most active Dental dealmakers since 2010
The report includes deals for the following indications: Dental caries, Mouth ulcer, Mucositis, Periodontal disease, Oral health, Xerostomia, plus other dental indications.
In Global Dental Partnering 2010 to 2020, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Dental Partnering 2010-2020 report provides comprehensive access to available deals and contract documents for over 250 dental deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Global Immunology Partnering 2014 to 2020 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Immunology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Immunology partnering...
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products...
The global UV/visible spectroscopy market is projected to reach USD 1.2billion by 2025 from USD 1.0billion in 2020 at a CAGR of 4.7%. Growth in UV/visible Spectroscopy market is mainly driven by factors such as application of UV/visible spectroscopy in environmental screening, growing use of UV/visible spectroscopy in pharmaceutical & biotechnology...
The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period. The global mycoplasma testing industry’s growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical...
Global Hematology Partnering 2010 to 2020 provides the full collection of Hematology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010. Trends in Hematology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hematology partnering...
The Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in biomarker partnering deals Biomarker...
The Global Drug Delivery Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Drug Delivery agreements announced...
Gastroenteritis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Pipeline Review, H2 2020, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape. Gastroenteritis is an infection of the gut. Symptoms...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.